Introduction: The Personal and the Professional
In the high-stakes world of metastatic breast cancer (MBC) research and patient advocacy, the line between the personal and the professional often blurs. For Kelly Shanahan, M.D., President of METAvivor, this duality is not merely a challenge—it is the driving force behind a relentless pursuit of better outcomes. In a recent communication to the community, Dr. Shanahan shared a candid update that underscores both the volatile nature of MBC and the critical importance of evolving clinical strategies.
As the summer transition into autumn, Dr. Shanahan’s message serves as a reminder that time is a precious commodity for those living with Stage IV cancer. While her own personal journey has seen unexpected hurdles—including a foot injury caused by her rambunctious eight-month-old puppy, Albus Dumbledore—the focus of her leadership remains steadfast on the systemic improvements needed to change the trajectory of the disease.
The Reality of Progression: A Clinical Case Study
Dr. Shanahan’s health update provides a sobering look at how metastatic breast cancer can shift, mutate, and adapt to therapy. Initially, a clinical trial drug had shown promising results in specific areas of her body. However, the nature of MBC is notoriously heterogenous.
The Mutation Paradox
Dr. Shanahan reported that while the original sites of disease were responding, her cancer had undergone a significant biological shift. Her highly ER/PR+ (Estrogen Receptor/Progesterone Receptor positive) MBC mutated into a low ER/PR- (negative), HER2-low status, with evidence of progression to the liver.
This phenomenon, known as receptor conversion or clonal evolution, is a major challenge in oncology. It highlights the necessity of serial biopsies. As Dr. Shanahan notes, “It is so important when we have a mixed response to treatment that we get biopsies of the new spots if at all possible.” Furthermore, she emphasizes that liquid biopsies—blood tests designed to detect circulating tumor DNA and genetic mutations—are vital tools for oncologists when a patient shows signs of disease progression.
Current Treatment Strategy
In consultation with her "village of oncologists," Dr. Shanahan has transitioned to a new therapeutic regimen. Based on a high tumor mutational burden detected via liquid biopsy, she has commenced immunotherapy combined with oral chemotherapy (capecitabine/Xeloda). Preliminary signs are encouraging; she reports the resolution of numbness in an area previously affected by a new metastasis. The community awaits her upcoming scans at the end of August, which will provide a clearer picture of the efficacy of this new course of action.
Empowering Patients Through Biomarker Education
One of the core missions of METAvivor is to demystify the complex science behind MBC. Recognizing that patients are often overwhelmed by technical terminology, the organization is launching a comprehensive biomarker education program.
The "Stage IV Stampede and Summit"
Education will take center stage at the upcoming Stage IV Stampede and Summit, scheduled for October 5, 2026. This event, which precedes the organization’s Hill Day on October 6, will feature a dedicated panel on biomarkers. The goal is to provide patients and caregivers with the knowledge necessary to advocate for their own precision medicine options.
Beyond the Basics: Navigating Multi-Biomarker Complexity
For patients who present with more than one biomarker, the treatment landscape can be incredibly daunting. To address this, METAvivor is developing a webinar series slated for late fall. This initiative aims to guide patients through the nuanced decision-making process required when multiple treatment pathways intersect or compete, ensuring that patients are not just passive recipients of care, but active participants in their treatment planning.
Strategic Partnerships: Amplifying the Voice of MBC
Advocacy is most effective when it is collaborative. METAvivor has announced a strategic partnership with the Live from Stage 4 podcast, a platform renowned for its deep dives into the patient experience and clinical breakthroughs.
Bridging Research and Reality
The partnership is designed to bridge the gap between abstract research and the daily realities of life with MBC. Listeners can expect:
- Expert Interviews: Conversations with leading oncologists and researchers.
- Controversy and Breakthroughs: Open discussions on the latest developments in the field.
- Management Strategies: Practical segments on mitigating treatment side effects.
- Program Spotlights: Future episodes will highlight METAvivor’s specific initiatives, including peer-to-peer support networks and the R.I.S.E (Reach. Inform. Support. Empower) program.
Supporting the Pipeline: The Role of Patient Advocates
At the heart of METAvivor’s mission is the funding of high-impact research. This process is heavily reliant on the input of patient advocate reviewers, who provide a unique and essential perspective on which research projects should receive funding.
The Power of Patient Reviewers
For those who signed up to serve as patient advocate reviewers, the process is now underway. These individuals review letters of intent and grant applications, ensuring that the research funded by METAvivor aligns with the most pressing needs of the patient community. Dr. Shanahan emphasized that this input is not merely a formality—it is a cornerstone of the organization’s scientific strategy. For those interested in joining this effort in the coming year, applications remain open on the METAvivor website.
Looking Ahead: Advocacy and Fundraising
As 2026 draws to a close, METAvivor is intensifying its efforts to raise both awareness and capital.
Light Up MBC
The organization’s largest annual fundraiser, Light Up MBC, is scheduled for October 13. Led by Tami Bowling and a dedicated team, this event serves as a focal point for the community to unite, share stories, and generate the necessary resources to continue funding transformative research.
A Call to Action
Dr. Shanahan’s message concluded with a powerful reminder of the organization’s origin: "METAvivor exists for and because of you." The organization remains open to community-driven initiatives, whether through volunteerism, independent fundraising, or the proposal of new concepts that can move the needle on metastatic breast cancer survival rates.
Implications for the Future of MBC Care
The trajectory of Dr. Shanahan’s personal journey mirrors the broader mission of METAvivor: a constant, evolving battle against a shifting disease. By prioritizing biomarker testing, embracing the role of the patient as an advocate in research, and fostering partnerships that educate and empower, the organization is creating a blueprint for patient-centered care.
The implications for the broader MBC community are clear:
- Precision is Paramount: As cancers mutate, the "one-size-fits-all" approach is becoming obsolete. Real-time monitoring through liquid and tissue biopsies is critical.
- Education is a Survival Tool: The more informed a patient is about their specific biomarkers, the more effective they can be in advocating for tailored therapies.
- The "Village" Approach: From peer-to-peer support groups to interdisciplinary oncology teams, no one should face the complexity of Stage IV cancer in isolation.
- Research Funding is Urgent: Without the direct support of advocates, the research pipeline for late-stage metastatic cancers remains underfunded compared to earlier stages of the disease.
As the community prepares for the upcoming Stampede and the Light Up MBC event, the message from the organization’s leadership is one of urgency and unwavering hope. Even when the road takes unexpected turns—like a sudden mutation or a broken foot—the collective effort of the METAvivor community remains focused on the ultimate goal: turning metastatic breast cancer into a manageable, and eventually, curable condition.
For those navigating this path, the resources provided by METAvivor—from the upcoming biomarker panels to the partnership with Live from Stage 4—offer not just information, but a lifeline of support in an often isolating medical landscape. As Dr. Shanahan continues her own treatment, her commitment to the collective serves as a testament to the resilience of the human spirit in the face of profound adversity.
About the Author
